

FORESIGHT VCT PLC

Ordinary Shares | Factsheet | 30 September 2022



89.7p
NAV per Share



1.4%
NAV increase over Period
(1 Jul 2022 - 30 Sept 2022)




4.5p
Dividend per Share
(paid 24 Jun 2022 – 5.8% yield)



39.0%
5 Year NAV Total Return

Foresight VCT plc is a Venture Capital Trust aiming to provide private investors with regular dividends and capital growth from a diverse portfolio of 50 investments in fast growing unquoted companies in the UK.


5 YEAR NAV TOTAL RETURN PERFORMANCE (RE-BASED)



PORTFOLIO ACTIVITY

Despite the challenges posed by economic and global political uncertainty during the three months ended 30 September 2022, the Company successfully invested £4.2 million into two growing businesses, alongside one follow-on investment of £0.7 million. During the reported period, the Company also completed the exit of industrial fastener products supplier TFC and technology and software tool developer Codeplay, delivering impressive returns of 12.6x and 16.1x respectively to investors. The team continues to search for high quality businesses that demonstrate growth potential, a strong competitive position in their respective market niche and resilience.

SECTOR WEIGHTING (VALUE)



NEW INVESTMENTS

Copptech

Copptech is an innovative, rapidly growing anti-microbial technology business founded in 2016 in Chile and headquartered in the UK. A main driver for the investment is positioning Copptech as a UK business to facilitate commercial traction in North America and Europe. Copptech develops antimicrobial technologies using copper, zinc and organic active ingredients, which are added to materials or dispersions to kill bacteria, fungi and viruses on contact. Applications for Copptech's antimicrobial materials are wide-ranging and include preventing infections and transmission of viruses in medical facilities, extending the shelf life of perishable goods, reducing discolouration and odour in clothing, and providing mould, fungi and termite-resistant properties to building materials. The company is well positioned to accelerate the growth of its new business model and expand its client base to new international markets.



Date: **August 2022**

Size: **c.£2.5m**

Hexarad

Hexarad is a healthcare technology company, delivering teleradiology services to NHS and private healthcare customers. It gives healthcare providers access to faster diagnosis of medical images – CT, MRI and X-Ray – using proprietary allocation tools to distribute scans to a pool of remote radiologists. Since Foresight's investment in June 2021, the company has more than doubled its annual revenue and has been recognised as one of the UK's 50 fastest-growing start-ups by City A.M. This additional investment into Hexarad will accelerate the development of key strategic elements of the existing growth plan. These include the launch of Hexarad's out-of-hours offering, which will allow 24-hour reporting on an emergency basis at higher margins, as well as the development of OptiRad, the company's proprietary workflow management software offering.



Date: **August 2022**

Size: **c.£700k**

Ruleguard

Strategic Software Applications Ltd ("Ruleguard") is a leading provider of regulatory compliance solutions for the financial services industry. The company was established by founder and CEO John O'Dwyer in 2013 as a B2B software development consultancy. In 2016, ahead of the incoming Client Assets Sourcebook legislation, Ruleguard developed a software as a service ("SaaS") compliance workflow solution for regulated financial institutions, delivering critical top-down visibility for compliance teams, and saving its clients up to 50% in annual audit and compliance costs. The system has been designed to work across different jurisdictions and geographies, and presently supports customers in the UK, Ireland, Australia, Singapore, Switzerland and Hong Kong. Post-investment, the growth strategy is based on building out the current platform features to increase sales to existing clients, as well as expanding its sales force to grow revenues organically by attracting new customers.




Date: **August 2022**

Size: **c.£1.7m**

TOP TEN INVESTMENTS

Position	Company	Sector	% of NAV
1	Hospital Services Group	Healthcare	9.1%
2	Nano Interactive Group	TMT	6.1%
3	Specac International	Industrials	5.1%
4	Spektrix	TMT	4.3%
5	Fresh Relevance	TMT	3.0%
6	Roxy Leisure	Consumer & Leisure	2.9%
7	Datapath Group	TMT	2.6%
8	Protean Software	TMT	2.5%
9	Itad (2015)	Business Services	2.4%
10	TLS Management	Other	2.3%

5 YEAR DIVIDEND HISTORY



*2022 figure of 4.5p excludes the 4.0p dividend paid 21 October 2022

MEET THE BOARD

Margaret Littlejohns (Chair) has 19 years' experience in both commercial and investment banking. She is also a non-executive director (NED) of UK Commercial Property REIT Ltd.

Gordon Humphries has over 30 years' experience in financial services and is a Chartered Accountant. He is also a NED and audit chair of Maven Income and Growth VCT 5 plc and JPMorgan UK Smaller Companies Investment Trust plc as well as a director of the AIC.

Jocelin Harris has been a qualified solicitor since 1986 and runs Durrington Corporation, which provides finance and advice for small businesses. He is currently chair or NED of several companies in the UK and USA, including Unicorn AIM VCT plc.

Patty Dimond has over 30 years' experience in the consumer, retail and financial services sectors. She is a CFA charter holder and qualified as a chartered accountant. Patty is NED and audit chair of Hilton Food Group plc and Aberforth Smaller Companies Trust plc as well as trustee and audit chair of English National Opera (ENO) and the National Academy of Social Prescribing (NASP).

COMPANY DETAILS

Company Name	Foresight VCT plc
Launch Date	1997
Net Assets	c.£198.5m
Number of portfolio companies	50
Share Price	77.0p
NAV per share	89.7p
Movement in NAV (since last quarter)	1.4%
Discount to NAV	(14.2%)
Annual Management Charge (AMC)	2.0% (1.0% on cash balances over £20m)
Ongoing Charges Ratio (OCR)	2.0%
Expenses Cap	2.4%
ISIN	GB00B68K3716
SEDOL	B68K371
Year End	31 December
Annual Report & Accounts Published	April

SHARE BUYBACKS

Share buybacks are timed to avoid the Company's closed periods. Buybacks will generally take place, subject to demand, during the following times of the year and we aim to buy back at a 10% discount to NAV:

- **April**, after the annual report has been published
- **June**, prior to the half-yearly reporting date of 30 June
- **September**, after the half-yearly report has been published
- **December**, prior to the end of the financial year

ABOUT THE MANAGER

Foresight Group LLP was established in 1984 and currently manages c.£12.5bn (unaudited as at 30 September 2022) for more than 40,000 private investors and over 200 institutional investors, including some of the world's leading financial institutions.

Foresight Group LLP is the Company's Manager and is a wholly owned indirect subsidiary of Foresight Group Holdings Limited.

On 9th February 2021, **Foresight Group Holdings Limited's** shares were listed on the premium segment of the London Stock Exchange Main Market, under ticker "FSG". Foresight Group Holdings Limited was awarded the LSE's Green Economy Mark, which recognises companies that derive 50% or more of their annual revenues from products and services that contribute to the global green economy.
www.fsg-investors.com



For further information contact Foresight Group:

The Shard, 32 London Bridge Street, London, SE1 9SG
T: +44 (0)20 3667 8181 E: investorrelations@foresightgroup.eu

Important Notice This document has been issued and approved by Foresight Group LLP, which is authorised and regulated by the Financial Conduct Authority. This document is intended for information purposes only and does not create any legally binding obligations on the part of Foresight Group LLP. Without limitation, this document does not constitute an offer, an invitation to offer or a recommendation to enter into any transaction. We recommend that you seek advice from your own tax and legal advisers. The information contained in this document is based on material we believe to be reliable. However, we do not represent that it is accurate, current, complete or error free. Assumptions, estimates and opinions contained in this document constitute our judgement as of the date of the document and are subject to change without notice. Past performance should not be regarded as an indication of future results. The distribution of this document and availability of this product in certain jurisdictions may be restricted by law. You may not distribute this document, in whole or in part, without our express written permission.